LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Barasertib | 10 | uM | LJP5 | 72 | hr | 962 | 1465 | 10512 | 0.1394 | 0.1281 |
MCF 10A | Vemurafenib | 0.04 | uM | LJP5 | 72 | hr | 962 | 10399 | 10512 | 0.9892 | 0.9936 |
MCF 10A | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 962 | 10238 | 10512 | 0.9740 | 0.9848 |
MCF 10A | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 962 | 10309 | 10512 | 0.9806 | 0.9886 |
MCF 10A | Vemurafenib | 1.11 | uM | LJP5 | 72 | hr | 962 | 10108 | 10512 | 0.9615 | 0.9773 |
MCF 10A | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 962 | 8735 | 10512 | 0.8312 | 0.8954 |
MCF 10A | Vemurafenib | 10 | uM | LJP5 | 72 | hr | 962 | 4165 | 10512 | 0.3960 | 0.5283 |
MCF 10A | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 962 | 10758 | 10512 | 1.0234 | 1.0134 |
MCF 10A | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 962 | 10762 | 10512 | 1.0237 | 1.0136 |
MCF 10A | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 962 | 10851 | 10512 | 1.0323 | 1.0184 |
MCF 10A | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 962 | 11253 | 10512 | 1.0703 | 1.0397 |
MCF 10A | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 962 | 11572 | 10512 | 1.1008 | 1.0564 |
MCF 10A | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 962 | 11123 | 10512 | 1.0580 | 1.0328 |
MCF 10A | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 962 | 7377 | 10692 | 0.6900 | 0.7974 |
MCF 10A | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 962 | 5870 | 10692 | 0.5491 | 0.6830 |
MCF 10A | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 962 | 5066 | 10692 | 0.4739 | 0.6131 |
MCF 10A | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 962 | 4339 | 10692 | 0.4058 | 0.5427 |
MCF 10A | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 962 | 4065 | 10692 | 0.3803 | 0.5137 |
MCF 10A | Palbociclib | 10 | uM | LJP6 | 72 | hr | 962 | 2737 | 10692 | 0.2560 | 0.3510 |
MCF 10A | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 962 | 8699 | 10692 | 0.8137 | 0.8847 |
MCF 10A | PF562271 | 0.12 | uM | LJP6 | 72 | hr | 962 | 7356 | 10692 | 0.6881 | 0.7958 |
MCF 10A | PF562271 | 0.37 | uM | LJP6 | 72 | hr | 962 | 5456 | 10692 | 0.5103 | 0.6478 |
MCF 10A | PF562271 | 1.11 | uM | LJP6 | 72 | hr | 962 | 2906 | 10692 | 0.2719 | 0.3744 |
MCF 10A | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 962 | 1254 | 10692 | 0.1173 | 0.0785 |
MCF 10A | PF562271 | 10 | uM | LJP6 | 72 | hr | 962 | 369 | 10692 | 0.0345 | -0.2412 |